생물정신의학 (Korean Journal of Biological Psychiatry)

  • 제18권4호
  • /
  • Pages.245-253
  • /
  • 2011
  • /
  • 1225-8709(pISSN)
  • /
  • 2005-7571(eISSN)
대한생물정신의학회 (The Korean Society of Biological Psychiatry)
권호 표지

양극성 장애 환자에서 나타나는 식욕 및 섭식 행동의 특성 : 일반적 음식갈망-특질척도(G-FCQ-T)와 약물 관련 섭식행동 설문지(DR-EBQ)를 이용한 평가

Changes of Appetite and Eating Behavior in Bipolar Disorder Patients : Measurement with General-Food Craving Questionnaire-Trait and the Drug-Related Eating Behavior Questionnaire

  • 이선이 (서울특별시 은평병원 정신과) ;
  • 류승형 (성균관대학교 의과대학 삼성서울병원 정신과학교실) ;
  • 고효정 (서울특별시 은평병원 정신과) ;
  • 홍경수 (성균관대학교 의과대학 삼성서울병원 정신과학교실) ;
  • 남희정 (서울특별시 은평병원 정신과)
  • Lee, Sunny (Department of Psychiatry, Seoul Metropolitan Eunpyeong Hospital) ;
  • Ryu, Seung-Hyong (Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ko, Hyo-Jung (Department of Psychiatry, Seoul Metropolitan Eunpyeong Hospital) ;
  • Hong, Kyung-Sue (Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Hee-Jung (Department of Psychiatry, Seoul Metropolitan Eunpyeong Hospital)
  • 투고 : 2011.07.29
  • 심사 : 2011.08.25
  • 발행 : 2011.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives In the current study, we quantitatively estimated changes in appetite and eating behavior of bipolar disorder patients during the pharmacotherapy. We also investigated their contribution to the weight gain and their association with specific food-craving characteristics of the patients. Methods Subjects included forty-one bipolar disorder patients and fifty-six controls. Currently sustained natures of food craving were assessed using the General-Food Craving Questionnaire-Trait (G-FCQ-T) and changes in appetite and eating behavior were measured using the Drug-Related Eating Behavior Questionnaire (DR-EBQ). Results Compared to the control group, the patients' group showed significantly higher body mass index (t=2.028, p=0.045). The patients' group had significantly higher 'Preoccupation with food' factor score of G-FCQ-T (p=0.016) than that of the control group. Hierarchical multiple regression analysis showed that only 'preoccupation with food' factor independently predicted psychotropic medication-induced appetite change. Conclusions Appetite change while receiving psychotropic medication seems to be related to the weight-gain and associated with craving natures of 'preoccupation with food' in bipolar disorder. Appetite and/or eating behavioral changes measured by G-FCQ-T and DR-EBQ could be regarded as an important mediating factor in future studies exploring biological mechanisms of weight gain related with pharmacotherapy for bipolar disorder.

키워드

참고문헌

  1. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60:215-220. https://doi.org/10.4088/JCP.v60n0402
  2. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000;61:179-184. https://doi.org/10.4088/JCP.v61n0306
  3. Smith DE, Marcus MD, Lewis CE, Fitzgibbon M, Schreiner P. Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults. Ann Behav Med 1998;20:227-232. https://doi.org/10.1007/BF02884965
  4. Gilmore J. Body mass index and health. Health Rep 1999;11:31-43; 33-47.
  5. Japanese Ministry of health, Labour and Welfare, 2003. Health and nutrition survey in 2003.
  6. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002;63:528-533. https://doi.org/10.4088/JCP.v63n0611
  7. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004;65:634-651, quiz 730. https://doi.org/10.4088/JCP.v65n0507
  8. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486-491; quiz 492-493. https://doi.org/10.4088/JCP.v62n0614
  9. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-430. https://doi.org/10.1111/j.1399-5618.2005.00234.x
  10. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987;499:203-215.
  11. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]. Encephale 2005;31:507-516. https://doi.org/10.1016/S0013-7006(05)82412-1
  12. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999;60 Suppl 21:16-19.
  13. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004;174:477-489.
  14. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65 Suppl 18:13-26.
  15. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15. https://doi.org/10.4088/JCP.v61n0104
  16. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-642. https://doi.org/10.4088/JCP.v61n0907
  17. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1-50. https://doi.org/10.1176/appi.ajp.159.1.1
  18. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005;66 Suppl 3:12-19.
  19. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17:781-791. https://doi.org/10.2165/00023210-200317110-00002
  20. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-244.
  21. Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006;119:478-481. https://doi.org/10.1016/j.amjmed.2005.11.003
  22. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999; 282:1530-1538. https://doi.org/10.1001/jama.282.16.1530
  23. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-1529. https://doi.org/10.1001/jama.282.16.1523
  24. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-567. https://doi.org/10.1176/appi.ps.54.4.565
  25. Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008;118: 4-18. https://doi.org/10.1111/j.1600-0447.2008.01204.x
  26. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: what mental health professionals need to know. Am J Psychiatry 2000;157:854-866. https://doi.org/10.1176/appi.ajp.157.6.854
  27. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
  28. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998;3:76-80. https://doi.org/10.1038/sj.mp.4000352
  29. Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, et al. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 2001;21:375-381. https://doi.org/10.1097/00004714-200108000-00004
  30. Theisen FM, Linden A, König IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003;110:111-121.
  31. El-Khatib F, Rauchenzauner M, Lechleitner M, Hoppichler F, Naser A, Waldmann M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007;16:226-232. https://doi.org/10.1016/j.seizure.2006.12.009
  32. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology 2002;46:67-69. https://doi.org/10.1159/000065414
  33. Lim M, Noh J, Nam H, Kim J, Lee D, Hong K. Development and validation of drug-related eating behavior Questionnaire in patients receiving antipsychotic medication. Korean J Schizophr Res 2008; 11:39-44.
  34. Noh J, Kim JH, Nam H, Lim M, Lee D, Hong K. Validation of the Korean version of the General Food Cravings Questionnaire-Trait (G-FCQ-T). Kor J Clin Psychology 2008;27:1039-1051.
  35. Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975;12:59-68. https://doi.org/10.1016/0022-3956(75)90021-7
  36. Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry 2003;64: 119-122. https://doi.org/10.4088/JCP.v64n0203
  37. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo- controlled study. Psychopharmacology (Berl) 2007;192:441-448. https://doi.org/10.1007/s00213-007-0731-1
  38. Sentissi O, Viala A, Bourdel MC, Kaminski F, Bellisle F, Olio JP, et al. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol 2009;24:257-264. https://doi.org/10.1097/YIC.0b013e32832b6bf6
  39. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA, et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 2008;16:1780- 1787. https://doi.org/10.1038/oby.2008.277
  40. Knolle-Veentjer S, Huth V, Ferstl R, Aldenhoff JB, Hinze-Selch D. Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation. J Psychiatr Res 2008;42:98-105. https://doi.org/10.1016/j.jpsychires.2006.10.003
  41. Nijs IM, Franken IH, Muris P. The modified Trait and State Food- Cravings Questionnaires: development and validation of a general index of food craving. Appetite 2007;49:38-46. https://doi.org/10.1016/j.appet.2006.11.001
  42. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57: 481-489. https://doi.org/10.1001/archpsyc.57.5.481
  43. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69. https://doi.org/10.1001/archpsyc.59.1.62
  44. Ryu S, Nam H, Oh S, Park T, Lim M, Choi J, et al. Atypical Antipsychotics-Induced Changes of Eating-Behavior in Patients with Schizophrenia Measured by the Drug-Related Eating Behavior Questionnaire (on submission).
  45. Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, Araujo de Baptista E, et al. Pharmacological management of atypical antipsychotic- induced weight gain. CNS Drugs 2008;22:477-495. https://doi.org/10.2165/00023210-200822060-00003
  46. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic- induced weight gain. J Clin Psychiatry 2001;62 Suppl 23:23-29.
  47. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13:27-35. https://doi.org/10.1038/sj.mp.4002066
  48. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006;31:2091-2120.
  49. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988;8:323-330.
  50. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-1435. https://doi.org/10.4088/JCP.v64n1205